[{"id":"c6408a7f-b48b-4ba4-933c-f55c568a4365","acronym":"CHOMP","url":"https://clinicaltrials.gov/study/NCT04104893","created_at":"2021-01-18T20:04:33.321Z","updated_at":"2025-02-25T16:09:31.539Z","phase":"Phase 2","brief_title":"A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation","source_id_and_acronym":"NCT04104893 - CHOMP","lead_sponsor":"VA Office of Research and Development","biomarkers":" EGFR • MSI • MLH1 • MSH6 • MSH2 • CDK12 • PMS1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["EGFR • MSI • MLH1 • MSH6 • MSH2 • CDK12 • PMS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Xtandi (enzalutamide) • abiraterone acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/20/2020","start_date":" 02/20/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-20"},{"id":"07c7a5d9-df0c-45c5-9b74-abae8c8d1379","acronym":"","url":"https://clinicaltrials.gov/study/NCT03751761","created_at":"2021-01-18T18:23:38.922Z","updated_at":"2024-07-02T16:35:17.456Z","phase":"Phase 1/2","brief_title":"GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study","source_id_and_acronym":"NCT03751761","lead_sponsor":"Asan Medical Center","biomarkers":" PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation","tags":["PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 06/11/2018","start_date":" 06/11/2018","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 08/30/2023","study_completion_date":" 08/30/2023","last_update_posted":"2024-02-28"},{"id":"fc21c219-c013-4138-9fe8-07a9c22cead0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05013216","created_at":"2021-08-19T14:52:56.438Z","updated_at":"2024-07-02T16:35:38.156Z","phase":"Phase 1","brief_title":"Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer","source_id_and_acronym":"NCT05013216","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1","pipe":" | ","alterations":" KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation","tags":["KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-09-04"}]